Could buspirone and lofexidine take the edge off opioid withdrawal?
NCT ID NCT05511909
First seen Jan 07, 2026
Summary
This Phase 2 trial tests whether adding buspirone (an anxiety medication) to lofexidine (a withdrawal drug) can reduce opioid withdrawal symptoms and cravings during detox. About 100 adults with opioid use disorder will stay in a residential setting for 10–12 days, undergo a stepwise opioid taper, and receive either the combo or a placebo. The goal is to see if the combination makes withdrawal more manageable and helps people transition to long-term treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANXIETY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kahlert Institute for Addictino Medicin
RECRUITINGBaltimore, Maryland, 21224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
buspirone and lofexidine
What this could lead to
If it works, this could offer a new medication combination to make opioid withdrawal less painful and reduce cravings, helping people complete detox more comfortably.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 100 participants. The results may not apply to everyone, and the combination might not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.